用于治疗皮肤黑色素瘤的癌基因导向小分子抑制剂。
Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma.
作者信息
Eliades Philip, Flaherty Keith T, Tsao Hensin
机构信息
Wellman Center for Photomedicine, Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Tufts University School of Medicine, Boston, MA 02111, USA.
出版信息
Melanoma Manag. 2015 May;2(2):133-147. doi: 10.2217/mmt.15.5. Epub 2015 May 18.
Achievements in cancer genetics and molecular biology have revolutionized the treatment options available for advanced melanoma. Patients with certain molecularly defined melanomas have been the most fortunate beneficiaries of recently US FDA-approved therapies that target aberrant MAPK pathway signaling, yet response rates and duration of response remain suboptimal. Furthermore, many patients harbor melanomas for which no approved targeted therapies currently exist. Since the approval of vemurafenib, a selective BRAF V600E inhibitor, in 2011, there has been a surge of preclinical and clinical studies aimed at developing novel targeted therapies for a wide range of molecularly defined melanomas. In this review, we will examine the present status and future potential of molecularly targeted therapies directed at the most significant oncogenic signaling pathways in melanoma.
癌症遗传学和分子生物学领域的进展彻底改变了晚期黑色素瘤的治疗选择。某些分子定义的黑色素瘤患者是美国食品药品监督管理局（US FDA）近期批准的针对异常丝裂原活化蛋白激酶（MAPK）通路信号传导疗法的最幸运受益者，但缓解率和缓解持续时间仍不尽人意。此外，许多患者所患黑色素瘤目前尚无获批的靶向治疗方法。自2011年选择性BRAF V600E抑制剂维莫非尼获批以来，针对多种分子定义的黑色素瘤开发新型靶向治疗方法的临床前和临床研究激增。在本综述中，我们将探讨针对黑色素瘤中最重要致癌信号通路的分子靶向治疗的现状和未来潜力。
Zotero 插件